MedTrace Logo

Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial

NCT01143948 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2010-06-15

No results posted yet for this study

Summary

Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths. In another prospective cohort study , cirrhosis accounted for 12.5% of deaths in patients with diabetes. In Egypt hepatitis C virus the commonest of cirrhosis here has a prevalence of 9.8% in the population with the greatest burden over national health care bills. Patients with cirrhosis \& type 2 diabetes mellitus are always showing up in all hospital wards without a clear consensus of best management of their hyperglycemia.

Conditions

Interventions

DRUG

Glargine & Glulisine

Basal Glargine \& bolus Glulisine

DRUG

Regular insulin

Sliding scale regular insulin

DRUG

NPH & regular insulin

Basal NPH \& bolus regular insulin

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Cairo University

    lead OTHER

Principal Investigators

  • Ibtisam Z Eissa, MD · Cairo University

  • Mary N Rizk, MD · Cairo Univerity

  • Ahmad A Khairy, MD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-04-30
Completion
2011-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01143948 on ClinicalTrials.gov